Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies by Fauvelle, Catherine (Catherine Fauvelle (fauvelle@unistra.fr)) (author) et al.
Hepatitis C virus vaccine candidates inducing protective 
neutralizing antibodies
Catherine Fauvelle1,2, Che C. Colpitts1,2, Zhen-yong Keck3, Brian G. Pierce4, Steven K.H. 
Foung3, and Thomas F. Baumert1,2,5,*
1Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, 
France
2Université de Strasbourg, 67000 Strasbourg, France
3Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
4Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA
5Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, 
67000 Strasbourg, France
Abstract
Introduction—With more than 150 million chronically infected people, hepatitis C virus (HCV) 
remains a substantial global health burden. Direct-acting antivirals have dramatically improved 
viral cure. However, limited access to therapy, late stage detection of infection and re-infection 
following cure illustrate the need for a vaccine for global control of infection. Vaccines with 
induction of neutralizing antibodies (nAbs) have been shown to protect successfully against 
infections by multiple viruses and are currently developed for HCV.
Areas covered—Here we review the progress towards the development of vaccines aiming to 
confer protection against chronic HCV infection by inducing broadly nAbs. The understanding or 
viral immune evasion in infected patients, the development of novel model systems and the recent 
structural characterization of viral envelope glycoprotein E2 has markedly advanced our 
understanding of the molecular mechanisms of virus neutralization with the concomitant 
development of several vaccine candidates.
Expert commentary—While HCV vaccine development remains challenged by the high viral 
diversity and immune evasion, marked progress in HCV research has advanced vaccine 
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development. Several vaccine candidates have shown robust induction of nAbs in animal models 
and humans. Randomized clinical trials are the next step to assess their clinical efficacy for 
protection against chronic infection.
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1. Introduction
With more than 150 million people infected worldwide, hepatitis C virus (HCV) infection 
remains a major global health concern. Following a generally asymptomatic initial infection, 
a large majority of patients develop chronic hepatitis and are subsequently at risk to progress 
to liver cirrhosis and hepatocellular carcinoma (HCC) within twenty years.[1] Various 
parameters may accelerate disease progression, such as alcohol consumption and human 
immunodeficiency virus (HIV) co-infection.[1] Twenty-five years after the discovery of 
HCV, the development of a prophylactic vaccine remains a major challenge.[2–7] This is 
largely due to the high mutation rate of HCV and numerous other strategies employed by the 
virus to escape host immune responses.[4]
Recent approval of direct-acting antivirals (DAAs) has greatly improved the outcome for 
treated patients, with cure now possible for the majority of cases.[8] Despite being highly 
effective, DAA treatments present important drawbacks, one being limited access due too 
high cost.[9] The current price of a DAA treatment course reaches thousands of dollars, 
while it is estimated that approximately 80% of HCV-infected individuals are living in low- 
and middle-income countries.[10] Even with production of generics, it remains unclear 
whether these will be accessible for these populations.[10] Importantly, in the absence of 
screening programs, a large proportion of chronic HCV carriers are unaware that they are 
infected and do not seek DAA treatment, thus potentially transmitting the infection.[9] 
Additionally, DAAs are less effective when patients are diagnosed at late stages, such as 
during hepatic decompensation or liver transplantation (LT).[8, 11, 12] Moreover, recent 
studies demonstrate that HCC risks persists following viral once liver fibrosis is established.
[9, 13]. Moreover, even a DAA capable of curing 100% of HCV-infected patients will not be 
able to protect patients from newly acquired infection. Re-infection following HCV cure 
remains possible – a major challenge in injection drug users.[14] These limitations 
underscore the need for a protective vaccine that can be employed in parallel with new 
treatments.
While the high viral diversity may preclude to develop a prophylactic vaccine, protecting all 
vaccines against HCV infection, modeling studies estimate that even a vaccine with a lower 
efficacy will have a substantial impact on HCV prevalence and incidence, especially in high 
risk populations,[15, 16] as well as important economic benefit.[17] It is of interest to note 
that it has been suggested, that even a partially effective vaccine would continue to have a 
substantial benefit even in the setting of highly effective treatments.[16] Collectively, these 
modeling approaches suggest that both an effective antiviral therapy as well as an efficient 
vaccine will be required to fully control HCV spread and eradicate viral infection on a 
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global level.[18] Furthermore, a parallel approach of treatment and vaccination appears to be 
in particular of relevance for populations at high risk for HCV infection such as intravenous 
drug abusers.
While vaccines inducing protective neutralizing antibodies (nAbs) have been successfully 
developed for many viral infections including hepatitis B,[19] poliovirus,[20] or human 
papillomavirus,[21] the development of a B cell vaccine with induction of neutralizing 
antibodies protecting against HCV infection has been a challenge[4]. B cell vaccines exert 
their major protective effect through the induction of cross-neutralizing antibodies.
The choice of an appropriate HCV immunogen is critical to anticipate and prevent viral 
escape[4]. NAbs are essential components of host immune responses elicited following 
HCV infection and several studies have demonstrated that nAbs clearly play a role for 
protection against HCV chronic infection.[22] NAbs are considered to mainly interfere with 
HCV entry which is a complex multistep process consisting of interactions between the viral 
envelope glycoproteins (GPs) E1/E2 and host cell entry factors.[23] Thus, HCV GPs play a 
major role in the initiation of hepatocyte infection and are the main target of nAbs. Several 
vaccine candidates evaluated in clinical trials are based on eliciting strong humoral immune 
responses by using HCV envelope proteins as immunogens (Table 1).[4, 24] A key aspect of 
this approach is the inclusion of highly conserved epitopes to overcome viral diversity and 
prevent viral evasion. Furthermore, consideration of highly conserved conformational 
epitopes for vaccine design is essential to deliver an antigen truly representative of 
neutralizing epitopes that are recognized in infected humans.[25, 26]
Two recent studies delineating the crystallographic structure of the HCV E2 core domain in 
complex with antigen-binding fragments of two distinct antibodies have greatly improved 
the understanding of HCV envelope glycoprotein (GP) structure. These structures are a 
major advance toward the utilization of conserved epitopes for rational vaccine design.[27, 
28] Aiming to address the progress and challenges of vaccine development, here we review 
the molecular mechanisms of virus neutralization, the impact of nAbs for control of viral 
infection in patients and provide an overview on vaccine candidates inducing nAbs which 
are in preclinical and clinical development.
2. Molecular mechanisms and targets of virus neutralization
E1 and E2 envelope glycoproteins are the natural targets of the protective antibody response. 
Since E2 interacts with the HCV co-receptors, scavenger receptor class B type 1 (SRB1)[29] 
and the tetraspanin CD81[30] during virus entry, the majority of nAbs are directed against 
E2. There is some evidence that the E1E2 heterodimer, not E2 alone, interacts with a third 
co-receptor, the tight junction protein claudin-1.[31] A major region mediating virus 
neutralization is the hypervariable region 1 (HVR1), encompassing the first 27 residues of 
E2.[32, 33] Antibodies to HVR1 are isolate-specific and over time will select viral 
quasispecies that are not recognized by these antibodies.[34] This region also blocks access 
of other broadly neutralizing antibodies to their cognate epitopes[35, 36] and the binding of 
antibodies to HVR1 was recently shown to interfere with the binding of broadly neutralizing 
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antibodies to E2 by steric hindrance.[37] Taken together, we believe that vaccine strategies 
should avoid the generation of HVR antibodies.
Antibodies with broad neutralizing activities mainly target conformational epitopes on E2 
(reviewed in [22]), with some directed against the E1E2 heterodimer.[38] Based on cross-
competition analyses and epitope mapping of broadly neutralizing human monoclonal 
antibodies (HMAbs) that were isolated from B cells of chronically infected patients, at least 
five clusters of overlapping conformational epitopes have been identified. Three clusters, 
designated as antigenic domains B, C and D, are composed of conformational epitopes on 
E2,[39–41] and two clusters, designated as antigenic regions (AR) 4 and 5, are composed of 
conformational epitopes on the E1E2 heterodimer.[38] It should be noted that the AR3 
cluster substantially overlaps with antigenic domain B, as identified by cross-competition 
and epitope mapping studies.[42] Interestingly, AR5 overlaps with an antigenic domain C 
HMAb, CBH-7, although the latter antibody binds to E2 and does not require E1.[38, 39] A 
sixth cluster of broadly nAbs to overlapping linear epitopes are located immediately 
downstream of HVR1, designated as antigenic domain E, encompassing amino acids 
412-423, that have been defined mainly by murine MAbs.[43–46]. It should be noted that 
neutralizing murine MAbs, typically generated via immunization with recombinant E2 
protein, have also been mapped to regions encompassing domains B, C and D but they tend 
to be antibodies to linear epitopes[22, 47] with decreased breadth of neutralization against 
different HCV genotypes[44]. However, some neutralizing murine MAbs that recognize 
conformational epitopes on E2 have been described.[44, 48]
Epitope mapping by alanine substitution studies identified two E2 residues, Gly530 and 
Asp535, that are required for binding by the majority of currently known domain B HMAbs.
[49] Residues Gly523 and Trp529 are also required for some, but not all, of these antibodies. 
Importantly, Trp529, Gly530 and Asp535 participate in the interaction of E2 with CD81.[50] 
Thus, antigenic domain B HMAbs exert broad neutralizing activities by competing with 
CD81 for binding to conserved residues on E2 that are necessary for this step in virus entry. 
Similarly, three critical residues form a core region for antigenic domain D epitopes at 
Leu441, Phe442 and Tyr443.[41] Leu441 and Tyr443 are absolutely conserved among all 
known HCV isolates.[51] Phe442, however, is only 84% conserved (LANL database). The 
domain D region is also involved in interaction with CD81. For AR4- and AR5-specific 
epitopes that require the E1E2 heterodimer, their associated antibodies do not mediate 
neutralization by inhibiting E2 interaction with CD81, but instead potentially block E1E2 
engagement with a different co-receptor or conformational changes in the E1E2 structure 
during virus entry.[38] With the elucidation of the E2 core structure,[27, 28] it became clear 
that the vast majority of nAbs, encompassing antigenic domain B and D, and AR3, engage 
the neutralizing face of E2 (Fig. 1A). However, critical residues for antigenic domain C, 
which mediates virus neutralization, are located on the “non-neutralizing” face, along with a 
cluster of conformational epitopes that do not mediate virus neutralization, designated as 
antigenic domain A (Fig. 1B).
Not all broadly neutralizing antibodies are created equally. In virus co-culture studies, some 
antigenic domain B antibodies are associated with viral escape (with and without 
compromising viral fitness), whereas others are not associated with escape. At a critical 
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antibody concentration of HC-1, a domain B HMAb, a complete elimination of infectious 
virions will occur.[52] These studies point to two discontinuous regions that participate in 
domain B epitopes, aa 425-443 and aa 529-535. The variable region aa 425-443 is 
responsible for escape and the conserved region aa 529-525 is responsible for virus 
interaction with CD81. Antibodies to antigenic domain E (aa 412-423) are also associated 
with different patterns of viral escape. Escape from virus neutralization with AP33 and 
HCV1 nAbs occurs when there is an N-glycan shift from Asn417 to Asn415 or residue 
substitutions at Asn415.[53–55] However, glycan shift-mediated escape is not associated 
with other antigenic domain E HMAbs, such as HC33.1.[56] A particular concern for 
antigenic domain E in vaccine design is that this region is not highly immunogenic in 
humans. The rate of HCV infected subjects with antibodies to this region ranges from 2–
15%[57, 58], while antibodies to antigenic domain B are frequently observed. Escape from 
antigenic domain D HMAbs (a subset of the antigenic domain B-D/AR3 supersite in Fig 
1A) has not been observed, despite some variability at critical binding residue Phe442, as 
noted above. Structural studies provided an explanation for the lack of viral escape in virus 
co-culture studies.[51] Three E2 residues, located at 441-443, form a hydrophobic 
protrusion that serves as the core binding site for domain D HMAbs. When Phe442Ile or 
Phe442Leu mutations are present, the interaction with the paratope formed by the heavy 
chain CDRs leads to a decrease in binding energy of the complex that can be compensated 
by increasing the antibody concentrations.
In summary, vaccine development should focus on specific epitopes within antigenic 
domains B and D that are not associated with viral escape and less on domain E that is of 
poor immunogenicity and possibly elicits neutralizing antibodies that are associated with 
viral escape without compromised viral fitness. Moreover, these studies illustrate the 
importance of functional and biochemical characterization of broadly reactive nAbs to create 
a high-resolution, functional map of neutralizing and non-neutralizing epitopes that can be 
employed for rational design of a B cell vaccine.
3. Viral evasion from neutralizing antibodies
The ability of HCV to adapt to its host is a major limitation for the development of a 
prophylactic vaccine. In patients, HCV circulates as a pool of quasispecies, viral variants 
which are genetically distinct and continually evolving due to a high viral mutation rate.[59] 
HCV variants reinfecting the liver graft are characterized by both enhanced entry in 
hepatocytes and escape from nAbs.[60] HCV has developed numerous strategies to avoid 
recognition by host humoral responses. HCV envelope glycoproteins (GPs) are the principal 
HCV proteins exposed during viral infection and the first target of humoral responses.[61] 
One study of over 26 years of HCV GP E1E2 sequences in a chronically infected patient 
demonstrated that humoral immunity applies a selective pressure to HCV, resulting in the 
continuous generation of variants with E1E2 mutations that are not neutralized by 
circulating nAbs.[34] Similarly, Dowd et al. observed that during the acute phase of HCV 
infection, the evolution of HCV GP sequences is driven by nAbs.[62] Nevertheless, the exact 
determinants of HCV genetic evolution and diversity are only partially understood and it is 
likely that although host selective pressure is a major determinant of viral quasispecies 
evolution, it is not the only one.
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Many mutations occur in specific regions called hypervariable regions (HVR) of HCV GPs. 
Farci et al. demonstrated a correlation between HCV diversity and viral clearance. Patients 
infected with a relatively stable HCV population are more susceptible to viral clearance, 
whereas chronicity correlates with genetic variability and evolution, especially in HVR1 of 
HCV GP E2.[63] The importance of this region for HCV persistence has been further 
confirmed by several studies demonstrating that HVR1 deletion increases the exposure of 
conserved epitopes facilitating virus neutralization by monoclonal antibodies and patient 
sera in vitro and in vivo.[35, 36, 64] In addition to a direct shielding role of HVR1, it has 
recently been proposed that nAbs binding poorly to HVR1 may interfere with the binding of 
broadly nAbs to other antigenic domains, due to steric hindrance which ultimately favors 
viral persistence.[37]
Although HCV variability already represents a strong obstacle for the design of a B cell 
vaccine, HCV has also developed other mechanisms to avoid nAbs recognition. The N-
glycosylation of HCV E2 has been described as an important mechanism for viral escape 
from nAbs, by masking epitopes to which these antibodies bind.[65–67] More precisely, five 
E2 glycans have been associated with a decreased sensitivity of HCV to nAbs, with four of 
them shielding CD81 binding sites that are highly targeted by nAbs.[66] Furthermore, under 
selection pressure, a shift in the glycan attachment site within the CD81 binding epitope on 
E2 can also occur, which decreases the efficacy of nAbs.[54] The capacity of HCV to 
disseminate using cell-to cell transmission has also been described as an efficient strategy to 
avoid the extracellular compartments where nAbs circulate.[68, 69] Interestingly, host 
targeting agents such as anti-receptor antibodies are able to prevent HCV cell-to-cell 
transmission, as well as DAA resistance related to this process.[70–73] Other studies also 
demonstrated that mutations in HCV GP E2 may alter the use of host-receptors CD81 and 
scavenger receptor B1, thus conferring resistance to nAbs.[74, 75] In patients, circulating 
HCV is associated with lipoproteins and forms hybrid lipo-viral particles (LVP). These 
associations have been shown to reduce the access of nAbs to their epitopes, facilitating 
HCV persistence.[75, 76] A recent study further demonstrated that host apolipoprotein E 
present at the surface of the LVP mediates evasion from nAbs.[77]
4. Impact of neutralizing antibodies for control of HCV infection: lessons 
from clinical cohorts
Since the discovery of HCV in 1989, many studies have focused on host immune responses 
following viral infection to elucidate the contributions of both cellular and humoral 
immunity for control and protection against HCV infection. The development and 
improvement of in vitro models for HCV has provided essential tools to elucidate the exact 
roles played by nAbs during the early phase of HCV infection.[78] Pseudotyped retroviral 
particles expressing HCV E1E2 glycoproteins (HCVpp) have been extensively used to 
evaluate the neutralization capacities of HCV-infected patient sera. Pestka et al. used sera 
from a cohort of pregnant women accidentally infected with a single HCV strain and 
followed for over 17 years.[79] Generation of HCVpp bearing the GPs of this specific strain, 
followed by neutralization experiments, revealed that viral clearance is associated with early 
appearance of nAbs during the early phase of HCV infection. The titer of nAbs then 
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diminished following viral clearance. In contrast, women who developed chronic hepatitis 
only presented an absent or low titer of nAbs during the initial phase of HCV infection, and 
the titer increased only during the late phase of infection.[79] Similarly, Osburn et al. 
evaluated the breadth of nAbs produced during the acute phase of HCV infection and 
observed that spontaneous control of viral infection is associated with a rapid production of 
broad nAbs. In contrast, patients who developed persistent infection had a delayed 
appearance of broad nAbs.[80] Importantly, the study of a patient who spontaneously 
recovered from HCV chronic infection highlighted that the appearance of nAbs at week 48 
was followed by viral clearance at 65 weeks post-infection, confirming their key role for the 
control of HCV infection.[81]
The importance of nAbs for protection against HCV recurrence has been further 
demonstrated in a retrospective study of patients with advanced hepatitis B virus (HBV) or 
HCV infection undergoing LT and who were treated with HBV immunoglobulins (HBIG). 
These HBIG were potentially contaminated with anti-HCV nAbs, due to the absence of 
HCV serological screening before 1990.[82] Interestingly, patients infected with HCV 
before LT and treated with HBIG had a lower incidence of HCV viremia after 
transplantation, compared to patients who did not receive HBIG or received HBIG after 
March 1990.[82] Moreover, patients who were HCV-negative before LT and received HBIG 
were less susceptible to acquire HCV infection than non-treated patients.[82]
Because they are frequently exposed to HCV, people who inject drugs have been included in 
many cohorts to study HCV recurrence. Osburn et al. observed that while only 25% of HCV-
infected people are able to spontaneously clear a primary infection, a clearance rate of 83% 
is observed after HCV re-exposure.[83] Additionally, patients clearing the secondary 
infection generate broad humoral immune responses, whereas these cross-nAbs are rarely 
detected in patients developing chronic infection.[83] These studies clearly demonstrate the 
crucial role played by nAbs to protect against HCV infection. It is important to note that 
neutralizing antibodies are considered to exert their function in concert with T cell responses 
which have been shown to play a key role for HCV control and clearance.[81, 84–88] 
Furthermore, recent data from clinical cohorts with acute HCV infection demonstrate an 
important role for T cell responses in the induction of B cell responses.[89] Indeed, in HCV-
infected patients, the presence of HCV-specific CD4+ T cells expressing markers of 
follicular T-helper (Tfh) cells and secreting interleukin 21 following viral exposure were 
observed.[89] Furthermore, expression of inducible T-cell co-stimulator was associated with 
induction of HCV-specific antibodies in patients with acute HCV infection.[89]
5. B cell vaccine candidates in preclinical and clinical development
One of the first approaches in vaccine development was the concept of a subunit vaccine 
based on recombinant envelope glycoproteins. Early studies of the Houghton group at 
Chiron showed that immunization of seven chimpanzees with recombinant E1/E2 
glycoproteins derived from genotype 1a induced nAbs that appeared to protected five of the 
seven animals from homologous HCV challenge.[90, 91] Furthermore, the vaccine reduced 
rates of chronic infection following homologous and heterologous HCV challenge,[92] an 
important finding given that most HCV-associated disease occurs during chronic infection.
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The recombinant E1E2 vaccine combined with MF59 adjuvant was then evaluated in a phase 
I clinical trial with 60 healthy volunteers.[93] The vaccine induced strong humoral and 
CD4+ T cell responses, and was well tolerated.[93] Studies with HCVpp demonstrated 
cross-neutralizing activity of the volunteer antisera against heterologous 1a, 1b and 2a HCV 
genotypes.[94] Using chimeric cell culture-derived HCV assays, Law et al. demonstrated 
that the recombinant E1E2 vaccine elicited broadly cross-nAbs in the volunteers, suggesting 
the presence of epitopes conserved among all major genotypes of HCV.[95] Indeed, peptide 
mapping and competition studies demonstrated that immunization with recombinant E1E2 
elicits antibodies targeting multiple cross-neutralizing epitopes.[96]
The recombinant E1E2-MF59 vaccine was further evaluated in a phase 1b study, either alone 
or in combination with pegylated-interferon (Peg-IFN) alpha2a and ribavirin for the 
retreatment of 78 treatment-experienced genotype 1a/1b patients.[97] The vaccine was safe 
and elicited E1E2 nAbs, which positively correlated with better treatment response. 
Although the vaccine alone did not induce significant changes in viral load, it was associated 
with a higher sustained virological response rate when used in combination with Peg-IFN/
ribavirin (RBV) (17% combined compared to 8% Peg-IFN/ribavirin alone).[97] This study 
suggests a potential for using HCV vaccines in combination with DAAs for difficult to treat 
patients or multiresistance.
The immunogenicity of an E1 candidate vaccine with aluminum hydroxide adjuvant was 
evaluated in a phase I study in 2004.[98] The individuals who received this vaccine 
developed humoral responses against E1, although the neutralization capacity of the 
antibodies was not evaluated.[98] Interestingly, when chimpanzees were vaccinated with 
either genotype 1b E1 or E2 recombinant protein with alum adjuvant, only antibodies 
against E1 were shown to neutralize HCVpp and protect the chimpanzees from persistent 
hepatitis following homologous challenge.[99] These findings highlight the importance of 
E1 for candidate HCV vaccines. Further insight into the structure and function of the E1/E2 
complex will likely improve our understanding of nAbs targets and contribute to further 
vaccine development.
HCV-like particles (LPs) derived from recombinant HCV structural proteins (core, E1 and 
E2) are morphologically similar to authentic HCV virions.[100] These HCV-LPs induce 
strong humoral and cellular immune responses in mice[101] and baboons,[102] but only 
limited B cell responses were observed in chimpanzees, despite strong induction of cellular 
immune responses.[103] Since HCV-LPs were produced in insect cells, they were likely not 
fully representative of authentic HCV virions, which may have limited their 
immunogenicity. Indeed, glycosylation of envelope glycoproteins is slightly different in 
insect cells,[100] which may explain the limited induction of nAbs. Pseudotyped virus-like 
particles expressing E1 and/or E2 envelope glycoproteins that were produced in mammalian 
cells induced cross-nAbs in macaques.[104] Inactivated cell culture-derived HCV virions 
induce cross-nAbs that confer protection from HCV infection in human liver chimeric mice.
[105] These findings suggest that virus-like particles produced in mammalian cells may 
better reflect the immunogenicity of authentic HCV virions with superior induction of nAbs.
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Vector-based immunization is also capable of inducing humoral immune responses in 
chimpanzees. A DNA vaccine encoding E2 prevented progression to chronicity in 
vaccinated chimpanzees, although did not induce sterilizing immunity.[106] In another 
chimpanzee study, vaccination with recombinant DNA (prime) and adenovirus (boost) 
vaccines expressing HCV core, E1E2 and NS3-5 genes induced long-lasting E2-specific 
antibody responses.[107] Although one vaccinated chimpanzee had sterilizing immunity 
against heterologous virus challenge, other vaccines with lower levels of E2-specific 
antibody developed chronic infections.[107] A therapeutic DNA vaccine expressing HCV 
structural proteins and NS3 was evaluated in a Phase I clinical trial of chronically infected 
patients who did not respond to previous IFN/RBV treatment.[108] All patients generated 
antibodies against core, and the majority (86.6%) of patients developed antibodies against 
E1. Following vaccination, 6 of the 15 patients previously lacking nAbs responses became 
positive for nAbs. Furthermore, over 40% of vaccinated individuals demonstrated improved 
liver histology (i.e. reduction in fibrosis), although this was attributed to cellular immune 
responses as opposed to nAbs.[108]
Interestingly, chimeric HBV/HCV vaccines have also been explored. These vaccines are 
based on the fact that the hepatitis B envelope protein (S) self-assembles into subviral 
particles, which constitutes the HBV vaccine in current use. Foreign epitopes, such as HCV 
envelope E1 and E2 protein sequences, can be inserted into the S protein to generate 
chimeric subviral particles.[109] One such vaccine replaced the N-terminal transmembrane 
domain of the HBV surface antigen with the transmembrane domain of genotype 1a HCV 
E1 and E2.[110] Vaccination of rabbits induced a strong humoral response to both HBV and 
HCV envelope proteins. These antibodies demonstrated cross-neutralizing activity against 
heterologous genotype 1a, 1b, 2a and 3 HCVpp, while HBV responses showed no loss of 
activity.[110] Further evaluation in other animal models and humans is warranted.
Collectively, these studies from the past decades have indicated the potential for a protective 
B cell-based vaccine against HCV. Although humoral responses generated by vaccines will 
likely be able to play a key role for prevention of infection, induction of cellular immune 
responses will likely be required for efficient protection against chronic infection.[2–7, 9] 
Interestingly, for several of the above reviewed approaches, concomitant induction of T cell 
responses has been demonstrated.[93, 104, 111] Ultimately, immunogens inducing both 
humoral and cell-mediated immune responses may be the optimal approach to provide full 
protection against HCV infection and liver disease.
6. Expert commentary
Despite hopes raised following the approval of new highly effective therapies able to cure 
the majority of patients, in the absence of a vaccine, it is probable that treatment-induced 
HCV eradication will remain a dream. Indeed, limitations of these treatments, especially in 
term of costs and access, restrain their use in countries with limited resources, where HCV 
incidence is high. Furthermore, an important proportion of patients are unaware of being 
infected with HCV and may further transmit the disease, thus favouring HCV spread and 
persistence in the population. Finally, re-infection following treatment-induced cure limits 
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this approach in particular in injection drug users. Thus, an effective vaccine may be needed 
to control and eliminate HCV infection on a global level.
The development of B cell-based vaccines has been hampered by the high viral 
heterogeneity and efficient escape to host immune responses. The recent understanding of 
the molecular mechanisms of viral neutralization including the elucidation of the crystal 
structure of HCV envelope glycoprotein E2 has contributed to the identification of epitopes 
for cross-neutralizing antibodies.[27, 28] Detailed studies in patient cohorts have shown that 
neutralizing antibody responses are associated with control of infection, and B cell-based 
vaccine candidates show promise in preclinical animal models and clinical trials. Induction 
of T cell responses may further enhance the efficacy of vaccine candidates.[2, 4] Future 
preclinical and clinical studies will provide further insights to bring a protective vaccine 
closer to reality.
7. Five-year view
Vaccine development is a long and complex process characterized by decades between 
preclinical studies and licensure and large-scale production. Current HCV vaccine 
candidates in development are still at the beginning of this process and the full impact of 
various mechanisms of viral escape to host immune responses still remains to be seen. 
Recent clinical trials studies have shown promise to induce cross-neutralizing antibodies 
although their clinical proof-of-concept for protection against infection remains to be shown. 
The recent advances in understanding the structure of the viral envelope combined with 
novel animal models assessing protective immune responses[112] will accelerate the 
development of improved vaccine candidates which ultimately may protect against HCV 
infection. A continuing effort is needed to reach that goal which appears to be possible to 
achieve within the next decade.
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8. Key issues
• Hepatitis C virus (HCV) infection is a major global health concern, 
with approximately 170 million people infected worldwide at risk for 
life-threatening liver disease and cancer.
• While recently licensed DAAs cure the majority of HCV-infected 
patients, high costs and limited access are major challenges for global 
control and eradication.
• Key challenges for the development of B cell vaccines are viral 
heterogeneity and evasion
• Studies in clinical cohorts demonstrated that neutralizing antibodies 
play a crucial role in viral clearance among individuals who 
spontaneously resolve HCV infection as well as protection against 
HCV re-infection.
• B cell vaccine candidates have been shown to induce cross-neutralizing 
antibodies in clinical trials, however proof-of-concept for protection 
against HCV infection remains to be shown.
• Ultimately, applying immunogens inducing both humoral and cell-
mediated immune responses may offer the best approach for full 
protection against HCV infection and virus-induced liver disease.
• The recent advances in understanding the structure of the viral envelope 
combined with novel animal models assessing protective immune 
responses will accelerate the development of improved vaccine 
candidates
• A continuing effort is needed to develop a protective vaccine – a goal 
which appears to be possible to achieve within the next decade.
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Figure 1. Antibody binding supersites on the E2 surface
Antigenic domains and antigenic regions are grouped into four supersites (colored green, 
blue, cyan and red, circled by dashed lines), based on previous binding competition and 
alanine scanning studies, shown on A) the neutralizing antibody face (CD81-binding region) 
and B) the non-neutralizing face of E2. Key binding residues shared by multiple antibodies 
are labeled and shown in space fill, and representative mAbs are shown for each supersite. 
The E2 structure is from the isolate H77 E2 core crystal structure[27, 28]. N-terminal 
residues (aa 412-420) missing from the crystal structure were modeled using Rosetta[113] 
and the crystal structure of HCV1 bound to aa 412-423.[114] Glycan structures were added 
using the Glyprot web server[115] and are shown as orange sticks and labeled according to 
the order of their bound asparagine residues in the E2 sequence (N1-N11; N5 not visible). 
All antibodies shown are human, except for those denoted by asterisks, which are mouse-
derived (HCV1 is from human antibody transgenic mice).
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